Anne Vincent-Salomon

Dr. Anne Vincent-Salomon

Department of Diagnostic and Theranostic Medicine, Department of Pathology, INSERM U934, INSTITUT CURIE 26 rue d’ULM 75005 PARIS, FRANCE
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Cancer Cell
Verified
Journal Article
Closed access
ACAna Costa
Ana Costa
YKYann Kieffer
Yann Kieffer
ASAlix Scholer-Dahirel
Alix Scholer-Dahirel
FPFloriane Pelon
Floriane Pelon
BBBrigitte Bourachot
Brigitte Bourachot
FMFatima Mechta-Grigoriou
Fatima Mechta-Grigoriou

1 September 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
YKYann Kieffer
Yann Kieffer
HHHocine R. Hocine
Hocine R. Hocine
GGGeraldine Gentric
Geraldine Gentric
FPFloriane Pelon
Floriane Pelon
CBCharles Bernard
Charles Bernard
FMFatima Mechta-Grigoriou
Fatima Mechta-Grigoriou
A subset of cancer-associated fibroblasts (FAP+/CAF-S1) mediates immunosuppression in breast cancers, but its heterogeneity and its impact on immunotherapy response remain unknown. Here, we identify 8 CAF-S1 clusters by analyzing more than 19,000 single CAF-S1 fibroblasts from breast cancer. We validate the five most abundant clusters by flow cytometry and in silico analyses in other cancer types, highlighting their relevance. Myofibroblasts from clusters 0 and 3, characterized by extracellular matrix proteins and TGFβ signaling, respectively, are indicative of primary resistance to immunotherapies. Cluster 0/ecm-myCAF upregulates PD-1 and CTLA4 protein levels in regulatory T lymphocytes (Tregs), which, in turn, increases CAF-S1 cluster 3/TGFβ-myCAF cellular content. Thus, our study highlights a positive feedback loop between specific CAF-S1 clusters and Tregs and uncovers their role in immunotherapy resistance. Significance: Our work provides a significant advance in characterizing and understanding FAP+ CAF in cancer. We reached a high resolution at single-cell level, which enabled us to identify specific clusters associated with immunosuppression and immunotherapy resistance. Identification of cluster-specific signatures paves the way for therapeutic options in combination with immunotherapies. This article is highlighted in the In This Issue feature, p. 1241

21 July 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ETEleonora Timperi
Eleonora Timperi
PGPaul Gueguen
Paul Gueguen
MMMartina Molgora
Martina Molgora
IMIlaria Magagna
Ilaria Magagna
YKYann Kieffer
Yann Kieffer
EREmanuela Romano
Emanuela Romano
Tumor-associated macrophages (TAM) play a detrimental role in triple-negative breast cancer (TNBC). In-depth analysis of TAM characteristics and interactions with stromal cells, such as cancer-associated fibroblast (CAF), could provide important biological and therapeutic insights. Here we identify at the single-cell level a monocyte-derived STAB1+TREM2high lipid-associated macrophage (LAM) subpopulation with immune suppressive capacities that is expanded in patients resistant to immune checkpoint blockade (ICB). Genetic depletion of this LAM subset in mice suppressed TNBC tumor growth. Flow cytometry and bulk RNA sequencing data demonstrated that coculture with TNBC-derived CAFs led to reprogramming of blood monocytes towards immune suppressive STAB1+TREM2high LAMs, which inhibit T-cell activation and proliferation. Cell-to-cell interaction modeling and assays in vitro demonstrated the role of the inflammatory CXCL12–CXCR4 axis in CAF–myeloid cell cross-talk and recruitment of monocytes in tumor sites. Altogether, these data suggest an inflammation model whereby monocytes recruited to the tumor via the CAF-driven CXCL12–CXCR4 axis acquire protumorigenic LAM capacities to support an immunosuppressive microenvironment. Significance: This work identifies a novel lipid–associated macrophage subpopulation with immune suppressive functions, offering new leads for therapeutic interventions in triple-negative breast cancer.

16 July 2018 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
PMPaula Michea
Paula Michea
FNFloriane Noël
Floriane Noël
EZEve Zakine
Eve Zakine
UCUrszula Czerwinska
Urszula Czerwinska
PSPhilémon Sirven
Philémon Sirven
VSVassili Soumelis
Vassili Soumelis

1 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHugo Croizer
Hugo Croizer
RMRana Mhaidly
Rana Mhaidly
YKYann Kieffer
Yann Kieffer
GGGeraldine Gentric
Geraldine Gentric
LDLounes Djerroudi
Lounes Djerroudi
FMFatima Mechta-Grigoriou
Fatima Mechta-Grigoriou
Although heterogeneity of FAP+ Cancer-Associated Fibroblasts (CAF) has been described in breast cancer, their plasticity and spatial distribution remain poorly understood. Here, we analyze trajectory inference, deconvolute spatial transcriptomics at single-cell level and perform functional assays to generate a high-resolution integrated map of breast cancer (BC), with a focus on inflammatory and myofibroblastic (iCAF/myCAF) FAP+ CAF clusters. We identify 10 spatially-organized FAP+ CAF-related cellular niches, called EcoCellTypes, which are differentially localized within tumors. Consistent with their spatial organization, cancer cells drive the transition of detoxification-associated iCAF (Detox-iCAF) towards immunosuppressive extracellular matrix (ECM)-producing myCAF (ECM-myCAF) via a DPP4- and YAP-dependent mechanism. In turn, ECM-myCAF polarize TREM2+ macrophages, regulatory NK and T cells to induce immunosuppressive EcoCellTypes, while Detox-iCAF are associated with FOLR2+ macrophages in an immuno-protective EcoCellType. FAP+ CAF subpopulations accumulate differently according to the invasive BC status and predict invasive recurrence of ductal carcinoma in situ (DCIS), which could help in identifying low-risk DCIS patients eligible for therapeutic de-escalation.

11 April 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
JMJustine Marsolier
Justine Marsolier
PPPacôme Prompsy
Pacôme Prompsy
ADAdeline Durand
Adeline Durand
ALAnne-Marie Lyne
Anne-Marie Lyne
CLCamille Landragin
Camille Landragin
CVCéline Vallot
Céline Vallot